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Abstract. Chronic wound management represents a signifi‑
cant burden on healthcare systems and negatively impacts 
on the quality of patient life. New strategies to understand 
and identify wounds that will not heal in a normal manner 
are required. Tumour endothelial marker‑8 (TEM‑8) has 
been implicated in the wound healing and angiogenesis 
processes. TEM‑8 expression was examined at the transcript 
level in a cohort of acute (n=10) and chronic (n=14) wounds 
and in normal skin (n=10). Protein analysis of TEM‑8 was 
also undertaken for this cohort using immunohistochem‑
istry (IHC). TEM‑8 impact on keratinocyte cell growth and 
migration was assessed following TEM‑8 ribozyme transgene 
transfection of human HaCaT keratinocytes using cell growth 
and electric cell‑substrate impedance sensing (ECIS)‑based 
assays. Expression of TEM‑8 was observed to be increased 
in acute wounds compared to chronic wounds and normal 
skin using quantitative polymerase chain reaction transcript 
analysis and IHC staining of wound tissues. Knockdown of 
TEM‑8 in HaCaT cells, using two independent ribozyme 
transgenes, resulted in significant decreases in cell growth as 
well as reductions in the rate of migration assessed using an 
ECIS‑based system. TEM‑8 may be differentially expressed 
between wound types and loss of this molecule impacts HaCaT 
growth and migration, potentially implicating this molecule as 
a factor involved in successful progression of wound healing.
Introduction
The management of chronic wounds is a significant drain 
on healthcare resources; the cost of wounds to the United 
Kingdom healthcare system alone is estimated to be ~£1 billion 
per year (1), notwithstanding the economic loss and impaired 
quality of life experienced by people with chronic ulcers. 
Identification of the molecular factors underlying chronic 
and acute wounds is critical for developing improved tailored 
treatments for wound healing.
In acute wounds caused by trauma to intact skin, normal 
wound healing involves three overlapping dynamic phases of 
inflammation (lasting 1‑3 days), proliferation (lasting 3‑14 days) 
and remodelling (can last up to several months) (2,3). However, 
in chronic wounds, 70% of which is represented by venous 
leg ulcers, often underlying disease states reduce healing and 
this dynamic process does not proceed in an orderly or timely 
manner to produce anatomic and functional skin integrity 
within 3 months, as observed in acute wounds (4).
The biology of skin healing in acute and chronic wounds 
involves complex interactions between epidermal and dermal 
cells, the extracellular matrix and plasma‑derived proteins (5). 
Currently, research is focusing on understanding the role of 
angiogenesis in physiological and pathological processes, such 
as inflammation, wound healing and tumour angiogenesis.
Tumour endothelial marker‑8 (TEM‑8) is a highly 
conserved type 1 transmembrane protein that was originally 
identified based on its overexpression in the endothelial cells 
lining the tumour vasculature of human colorectal cancer (6). 
The present understanding of the physiological function of 
TEM‑8 is limited; the high level of conservation of TEM‑8 
among different species suggests that TEM‑8 has a funda‑
mental role in normal physiology, as well as pathological 
processes. TEM‑8 has been found to bind to collagens and 
promote migration of endothelial cells in vitro (7,8), and thus 
have a potential role in angiogenesis (9‑11) and wound healing.
TEM‑8 is upregulated in tumour vasculature in mice 
and humans (7,12,13), and is also expressed by tumour cells 
themselves in certain cancer types (12,14,15). However, 
TEM‑8 could not be detected in the angiogenic corpus luteum 
of human ovaries (6,7) and thus presents itself as a unique 
target for selectively blocking pathological angiogenesis. 
Previous studies have shown that the genetic disruption and 
antibody‑mediated disruption of TEM‑8 in mice inhibited 
tumour angiogenesis and growth, but did not perturb acute 
wound healing observed for ≤7 days (16,17). However, the 
role of TEM‑8 in chronic non‑healing wounds has not been 
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investigated previously. Inhibition of angiogenesis is known 
to impair wound healing (18‑20) and previous studies have 
revealed potential microenvironmental factors, specifically a 
reduction in tissue growth factors, which is known to impair 
healing (21), have now been shown to also induce TEM‑8 
expression (16,22).
The present study investigated the role of TEM‑8 in 
wound healing processes, specifically its expression in clinical 
chronic wound samples and its influence on HaCaT growth 
and migrational rates.
Materials and methods
Materials. A universal immunohistochemical kit, Elite ABC 
kit, was purchased from Vector Laboratories (Peterborough, 
UK). The total RNA isolation reagent was purchased from 
Sigma‑Aldrich (Dorset, UK) and reverse transcription kits 
(iScript) were obtained from Bio‑Rad Laboratories (Hemel 
Hempstead, UK).
Skin biopsies. Skin biopsies were obtained from patients 
attending the University Hospital of Wales (UHW, Cardiff, UK) 
wound healing clinic, as described previously (23,24). Ethical 
approval was granted by the Local Research Ethics Committee. 
Written informed consent was obtained from each patient.
Chronic wound tissue. Biopsies from 14 patients with chronic 
leg ulcers were used during the study. Venous disease was 
diagnosed by duplex ultrasonography and all the wounds were 
present for ≥6 months, with no evidence of healing occurring 
6 weeks before biopsy. The wounds had a minimum area of 
4 cm2 prior to biopsy and had no clinical indications of infec‑
tion. Using an aseptic technique, 6‑mm punch biopsies were 
removed, following the application of local anesthetic (1% lido‑
caine), from the wound margin, incorporating epidermis and 
dermis at the wound edge with adjacent granulation tissue.
Acute wound tissue. Single wedge biopsies were obtained 
from 10 patients with acute surgical wounds subsequent to 
undergoing excision of pilonoidal disease. These wounds 
were judged to be clinically noninfected. The biopsies were 
obtained from the edge of the healing wound within 6 weeks 
from the surgical excision.
Normal skin tissue. To provide a comparison to wound tissue, 
normal skin tissue was also examined. Under local anesthetic, 
3‑mm punch biopsies were removed from the inner aspect of 
the upper arm of 10 healthy volunteers working within the 
Wound Healing Research Unit (School of Medicine, Cardiff 
University, Cardiff, Wales).
Immunohistochemical staining. Frozen sections from wound 
tissues were first fixed in an acetone/methanol solution and rehy‑
drated in wash buffer (MenaPath Autowash buffer; A. Menarini 
Diagnostics, Berkshire, UK) prior to placing the samples into 
a wash buffer solution containing 10% horse serum to aid in 
the blocking of non‑specific antigen binding. An avidin/biotin 
complex (ABC) immunohistochemistry (IHC) kit (Vector 
Laboratories, Nottingham, UK) was used in accordance with 
the manufacturer's protocol. A polyclonal antibody to TEM‑8, 
previously generated (9), was used and diluted in a buffer that 
contained 1% horse serum and 0.1% Tween‑20 at 1:40 dilution. 
After a 1‑h incubation period with the primary antibody, the 
slides were washed 4 times in a washing buffer and a universal 
biotinylated secondary antibody was added for 30 min. Following 
washing, avidin and biotin were added through the addition of 
the ABC complex. A DAB colour developing system was used 
to indirectly detect protein staining. Sections were dehydrated 
through a series of graded alcohols, cleared in xylene, mounted 
and evaluated on an Olympus microscope equipped with a 
digital camera (Olympus, Southend‑on‑Sea, UK).
HaCaT cell line and culture conditions. The HaCaT human 
keratinocyte cell line was purchased from the German Cancer 
Research Institute (Heidelberg, Germany). Cells were main‑
tained in Dulbecco's modified Eagle's medium supplemented 
with penicillin, streptomycin and 10% fetal calf serum (PAA 
Laboratories Ltd., Somerset, UK). The cells were incubated at 
37˚C, 5% CO2 and 95% humidity.
RNA extraction and reverse transcription‑polymerase chain 
reaction (RT‑PCR). Cells were grown to confluence in a 
25‑cm2 flask prior to RNA extraction using the total RNA 
isolation reagent in accordance with the manufacturer's 
protocol. Sample RNA was quantified using a spectropho‑
tometer (WPA UV 1101; Biotech Photometer, Cambridge, 
UK) and standardized to a concentration of 500 ng prior to 
being used as a template to reverse transcribe cDNA using an 
iScript cDNA synthesis kit (Bio‑Rad Laboratories). Following 
cDNA synthesis, samples were probed using glyceraldehyde 
3‑phosphate dehydrogenase (GAPDH) primers to check the 
cDNA quality and confirm uniform sample cDNA levels, 
together with those specific for TEM‑8 transcript (Table I) as 
previously reported (9,11).
Conventional RT‑PCR primers were designed using Beacon 
designer Software (Beacon Designer, Palo Alto, CA, USA), to 
allow amplification of regions that have no overlap with known 
genes and span at least one intron. Primers were synthesized by 
Invitrogen (Paisley, UK). Conditions for conventional RT‑PCR 
to amplify transcripts of TEM‑8 were: 94˚C for 40 sec, 54˚C for 
30 sec, 72˚C for 50 sec and a final extension phase of 10 min 
for 34‑36 cycles, with GAPDH used as the reference gene. The 
PCR products were separated on a 0.8% agarose gel and stained 
with ethidium bromide prior to examination under UV light.
RT‑quantitative PCR (RT‑qPCR). RT‑qPCR was used to 
determine the transcript expression levels of TEM‑8 in wound 
tissues. This methodology has been reported previously (25). 
Briefly, the iCycler IQ system (Bio‑Rad, Camberley, UK) was 
used to quantify the transcript level of TEM‑8 within each of 
the clinical samples. Results are provided as number of tran‑
scripts per microlitre and are based on an internal standard run 
and amplified in conjunction with the samples. Normalisation 
of samples was achieved through comparison of sample 
GAPDH levels. The Amplifluor system (Intergen Inc., New 
York, NY, USA) was used in conjunction with a universal 
probe (UniPrimer), which recognised a specific sequence 
(z sequence), incorporated into the primers. RT‑qPCR condi‑
tions were as follows: 95˚C for 15 sec, 54˚C for 20 sec and 
60˚C for 60 sec.
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TEM‑8 knockdown in the human HaCaT keratinocyte 
cell line. Hammerhead ribozyme transgenes, specifically 
targeted to TEM‑8 transcripts were constructed based on the 
secondary structure of TEM‑8 mRNA, as described previ‑
ously (10) (Table I). Following the design and synthesis by 
Invitrogen, two separate ribozymes, targeting different regions of 
the TEM‑8 transcript, were cloned into a mammalian pEF6/His 
TOPO vector (Invitrogen) and transfected into HaCaT cells, as 
previously reported (10). Following a period of blasticidin selec‑
tion (5 µg/ml), the cells were maintained in media containing 
0.5 µg/ml blasticidin. This process allowed the generation of 
stably transfected HaCaT cells containing the ribozyme trans‑
gene and expressing reduced TEM‑8 levels (HaCaTΔTEM‑8 rib1 
and HaCaTΔTEM‑8 rib3) and control HaCaT cells transfected with 
a closed pEF6 plasmid (HaCaTpEF6). Suppression of TEM‑8 
expression in HaCaTΔTEM‑8 rib1 and HaCaTΔTEM‑8 rib3 cells was 
verified, in comparison to HaCaTpEF6 controls, using RT‑PCR.
In vitro growth assay. The effect of TEM‑8 suppression on 
HaCaT cell growth rates was assessed using an in vitro growth 
assay. Cells were seeded at a density of 3,000 cells/well in 
96‑well plates. Triplicate plates were set up and incubated for 
3‑ and 5‑day periods before analyses. Following incubation, 
the plates were fixed in 4% formaldehyde (v/v) and stained 
with 0.5% (w/v) crystal violet and were subsequently treated 
with 10% acetic acid (v/v), prior to colorimetric detection of 
cell density by spectrophotometric analysis at 540 nm using a 
Bio‑Tek ELx800 mutliplate reader (Bio‑Tek Instruments Inc., 
Winnoski, VT, USA).
Electric cell‑substrate impedance sensing (ECIS) analysis of 
HaCaT migration. The ECIS 9600 system (Applied Biophysics 
Inc., Troy, NJ, USA) was used to detect and track HaCaT cell 
migration, as described previously (26,27). Briefly, cells were 
simultaneously plated in ECIS 8W10 arrays and incubated until 
a confluent monolayer had formed over the array electrodes. 
This monolayer was subsequently wounded electrically by 
applying 6V for a 30‑sec time‑period to create a simultaneous 
physical break in the cell monolayer of equal dimensions. The 
rate of change in resistance as cells migrated back onto the 
electrode, was subsequently monitored and measured using 
the ECIS software provided. Prior to use, ECIS arrays were 
treated with L‑cysteine solution for 40 min followed by several 
washes with complete medium to remove any particles present 
on the electrode.
Statistical analysis. The SigmaPlot 11 statistical package 
(Systat Software, San Jose, CA, USA) were used to identify 
statistical differences between the test groups using one‑way 
analysis of variance (ANOVA) or ANOVA on RANKS tests. 
P<0.05 was considered to indicate a statistically significant 
difference. All the in vitro functional assays were repeated a 
minimum of three times.
Results
TEM‑8 expression is decreased in non‑healing chronic 
venous leg ulcers compared to acute wounds. TEM‑8 is mini‑
mally expressed in all layers of the epidermis of normal skin. 
However, in acute wounds, expression of TEM‑8 increases 
within the cytoplasm of keratinocytes and endothelial cells, 
consistent with its putative role in angiogenesis. Expression 
was also increased in chronic wounds compared to normal 
skin, but is lower compared to the acute wounds (Fig. 1A‑C).
Consistent with the immunohistochemical analyses, 
RT‑qPCR detection and normalisation of TEM‑8 levels also 
revealed higher TEM‑8 expression in acute (median, 3.964; 
IQR, 12.049‑0.0445) and chronic (median, 1.755; 
IQR, 7.426‑0.144) wounds and again, extremely low levels were 
observed in normal skin (median, 0.381; IQR, 1.996‑0.0629), 
although no significant differences were observed within the 
group (P>0.05) (Fig. 1D).
Suppression of TEM‑8 expression reduces the growth rate 
of HaCaT keratinocytes. To determine the effect of reduced 
TEM‑8 expression on keratinocyte cell growth, HaCaT kerati‑
nocytes were transfected with ribozyme transgenes specifically 
targeted to the TEM‑8 transcript to reduce TEM‑8 transcript 
levels within HaCaT cells, as assessed by RT‑PCR (Fig. 2A).
In HaCaT keratinocytes in which TEM‑8 expression 
was reduced, a decrease was also observed in the in vitro 
growth rate of the HaCaT cells (Fig. 2B). The growth rate of 
HaCaTΔTEM‑8 rib1 and HaCaTΔTEM‑8 rib3 cells over a 5‑day incuba‑
tion period was significantly lower compared to the HaCaTpEF6 
control cells (P=0.004 and P=0.014, respectively). No signifi‑
cant differences between the groups were observed over a 
3‑day incubation period (P>0.05).
Suppression of TEM‑8 expression reduces the migrational 
rates of HaCaT cells. As TEM‑8 expression was reduced 
in non‑healing wounds compared to acute wounds and 
Table I. Primer and ribozyme sequences.
Primer/sequence Forward Reverse
TEM‑8 ribozyme 1 ctgcagggggccatagagacggctgatgagccgtga actagtccacagctattatgtgtttcgtcctcacggac
TEM‑8 ribozyme 3 gtgcagacttcttcaaaattgagtggatctgatgactccctga actagttttcaggctctgcaaggcatttcgtcctcacgga
TEM‑8 conventional catttcaagttgtcgtgaga gacgcatattgttgttgaga
TEM‑8 quantitative acagggtcctctgcagctt actgaacctgaccgtacactttcatgccaacttgttt
GAPDH conventional agcttgtcatcaatggaaat cttcaccaccttcttgatgt
GAPDH quantitative ctgagtacgtcgtggagtc actgaacctgaccgtacacagagatgatgacccttttg
actgaacctgaccgtacaca represents the z sequence. TEM‑8, tumour endothelial marker‑8; GAPDH, glyceraldehyde 3‑phosphate dehydrogenase.
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suppression of TEM‑8 expression also reduced cell growth, 
the effects of TEM‑8 knockdown on keratinocyte migra‑
tion directly were investigated. An ECIS assay was carried 
out to examine the effects of TEM‑8 suppression on HaCaT 
migration following electrical wounding (Fig. 3). Substantial 
differences between the migratory rates of HaCaTpEF6, 
HaCaTΔTEM‑8 rib1 and HaCaTΔTEM‑8 rib3 were observed as the cell 
lines responded to re‑colonise the wounded area of the array. 
HaCaTpEF6 cells migrated at a steady rate following wounding 
as indicated by the increase in resistance recorded across the 
array. In contrast to this, HaCaTΔTEM‑8 rib1 and HaCaTΔTEM‑8 rib3 
cells showed a reduced capacity to migrate into the wound and 
recover the monolayer over the experimental time (Fig. 3A). 
Three‑dimensional analysis further demonstrated this trend, 
showing changes in resistance across a range of tested frequen‑
cies and time for HaCaTpEF6 (Fig. 3B), HaCaTΔTEM‑8 rib1 (Fig. 3C) 
and HaCaTΔTEM‑8 rib3 (Fig. 3D).
Discussion
TEM‑8 is a cell surface receptor that has been shown to 
promote tumour angiogenesis. Given the importance of angio‑
genesis in tissue healing and repair, the role of TEM‑8 in acute 
and chronic wounds was investigated in the present study.
TEM‑8 expression was significantly higher in acute 
wounds, measured at 6 weeks, and chronic wounds, measured 
at 6 months, compared to normal skin tissue. Targeting TEM‑8 
expression, using a ribozyme transgene system in the HaCaT 
keratinocyte cell line, resulted in decreased growth after 
Figure 1. Expression of tumour endothelial marker‑8 (TEM‑8) in clinical wound and normal skin samples. Immunohistochemical staining analysis of TEM‑8 
expression in (A) acute and (B) chronic wounds, and (C) normal skin tissue sections demonstrating increased cytoplasmic TEM‑8 expression in keratinocytes 
and endothelial cells at the wound edge. (D) Quantitative transcript analysis of TEM‑8 levels in acute and chronic wounds, and normal skin.
Figure 2. (A) Reverse transcription‑polymerase chain reaction demon‑
strating successful knockdown of tumour endothelial marker‑8 (TEM‑8) 
following transfection of HaCaT cells with two independent TEM‑8 
ribozyme transgenes. (B) Knockdown of TEM‑8, using either ribozyme 
transgene, significantly reduced cell growth rate over a 5‑day incubation 
period in comparison to control cells. Representative data shown as average 
values ± standard deviation, **P<0.01 and *P<0.05.
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5 days and decreased migration within hours in an ECIS‑based 
assay. A similar role for TEM‑8 in promoting cell migration 
was observed in previous studies demonstrating that TEM‑8 
mediates spreading of endothelial cells in vitro (8).
In other studies, TEM‑8‑KO and anti‑TEM‑8 antibodies did 
not appear to affect acute wound closure rates or the amount of 
vasculature present within the acute wound granulation tissue 
in mice measured at 5‑7 days (16,17). Therefore, it is important 
to note that wound healing was assessed at different times 
(days versus weeks/months) and the experiments reported in 
the present study were performed in vitro on single HaCaT cell 
lines, and therefore it is difficult to compare the direct effects 
on a single cell line with observed physiological responses 
in animal models, whereby multiple mechanisms and cells 
participate in wound healing.
Notably, TEM‑8 expression was 2‑fold higher in the acute 
versus chronic wounds, but nearly undetectable in normal skin 
tissue, consistent with studies by Chaudhary and St Croix, 
which demonstrated that local environmental stressors, 
including growth factor deprivation, reduced levels of which 
are commonly observed in non‑healing wounds (21), led to 
TEM‑8 overexpression (16,22).
It has been proposed that TEM‑8 may be involved in a 
transient stress‑mediated response (16,22), and numerous 
stressors, such as hypoxia and low levels of growth factors, 
exist in the chronic wound microenvironment (18‑21,28). 
Persistent elevated levels of TEM‑8 in chronic wounds suggest 
that TEM‑8 could have a role in pathological angiogenesis in 
non‑healing wounds, as well as in tumours.
The notion that tumours represent ‘unhealed wounds’ is 
one of the oldest ideas in cancer biology (29) and it is perhaps 
not surprising that TEM‑8 could have a role in angiogenesis in 
both of these pathological processes.
An improved understanding of the mechanism and role 
TEM‑8 has in acute and chronic wounds requires further study 
and may allow for the development of more effective therapies 
for tumour angiogenesis and also chronic wound healing.
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Figure 3. Electric cell‑substrate impedance sensing analysis of cell migration. (A) Knockdown of tumour endothelial marker‑8 (TEM‑8) in HaCaT cells 
through transfection with either TEM‑8 ribozyme 1 or TEM‑8 ribozyme 3 reduced cell migration over an 8‑h period post electrical wounding in comparison 
to control cells. Three‑dimensional modelling of changes in resistance following electrical wounding over a range of frequencies and time are shown for 
(B) HaCaTpEF6, (C) HaCaTΔTEM‑8 rib1 and (D) HaCaTΔTEM‑8 rib3. Representative data shown as average values ± standard deviation.
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